-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Large multinational pharmaceutical companies have entered the field of traditional Chinese medicine, which has aroused widespread debate
in the industry.
01 Innovation in Chinese medicine, one step further
01 Innovation in Chinese medicine, one step furtherFollowing the cooperation between AstraZeneca and Chengdu High-tech Zone to build a traditional Chinese medicine innovation industry base, AstraZeneca chose to reach cooperation with Tianjin Institute of Materia Medica, and further went further in
the field of traditional Chinese medicine.
On November 2, at the "2022 Western Smart Medical Industry Summit", AstraZeneca Pharmaceutical (Chengdu) Co.
, Ltd.
and Tianjin Pharmaceutical Research Institute officially signed a strategic cooperation agreement
.
AstraZeneca Chengdu International Life Science Innovation Park mainly focuses on the inheritance of traditional Chinese medicine and providing an incubation platform and business support
for innovative enterprises.
In April this year, AstraZeneca's innovation base focusing on the field of traditional Chinese medicine officially settled in Chengdu
.
AstraZeneca has said that the Chinese medicine innovation industry base jointly built with Chengdu High-tech Zone will help AstraZeneca focus on the modernization and innovative development of traditional Chinese medicine and promote international exchanges
.
.
Six months later, AstraZeneca chose to increase the innovation
of traditional Chinese medicine again through cooperation.
The two sides said that this cooperation will help accelerate the output of traditional Chinese medicine varieties
.
of traditional Chinese medicine again through cooperation.
The two sides said that this cooperation will help accelerate the output of traditional Chinese medicine varieties
.
Tianjin Institute of Materia Medica, which cooperated with AstraZeneca, has taken the lead in the research and development of modern traditional Chinese medicine in China, independently developed and obtained 41 new drug certificates, and the varieties represented by quick-acting heart-saving pills, guizhi poria capsules, children's soybean Qingqing granules, Sanqi Tongshu capsules, Siji Sanhuang soft capsules, etc.
have brought good social benefits and economic value
to industrialized enterprises.
How much benefit can the large variety of traditional Chinese medicine bring to enterprises?
Taking quick-acting heart-saving pills as an example, as the core variety of Jinyao Darentang, it is a protected variety of national traditional Chinese medicine and a necessary proprietary Chinese medicine for emergency departments in Chinese medicine hospitals across the country, and has been selected into the national essential drugs list and the national medical insurance list
.
In 2021, the cumulative sales revenue of Quick-acting Heart-saving Pills will be 1.
3 billion yuan, a year-on-year increase of 9.
47%.
3 billion yuan, a year-on-year increase of 9.
47%.
It can be seen that if similar varieties of traditional Chinese medicine can be produced through cooperation, it will bring considerable benefits
to AstraZeneca.
However, creating large varieties is not an easy task
for pharmaceutical companies.
Dong Zecheng, marketing director of a domestic pharmaceutical company, told Cyberblue that under the normalization of centralized procurement, it is very difficult for enterprises to create more than 100 million varieties as before, and now many large varieties are achieved in the period of rapid growth of medicine
.
02 AstraZeneca does Chinese medicine, what it may do
02 AstraZeneca does Chinese medicine, what it may doFor AstraZeneca, it has long had certain experience
in the field of traditional Chinese medicine.
In 2019, AstraZeneca signed an agreement with Luye Pharmaceutical Group to officially announce the exclusive promotion rights
of Xuezhikang capsules in Chinese mainland.
of Xuezhikang capsule products in Chinese mainland.
As the first time that a large multinational pharmaceutical company has been given full authority to promote innovative prescription proprietary Chinese medicines independently developed by Chinese pharmaceutical companies in China, the market performance of Xuezhikang has lived up to expectations
.
From 2019 to the end of 2021, the sales volume of Xuezhikang increased by nearly 120%, becoming the third largest lipid-lowering brand
in the overall statin and lipid-lowering proprietary Chinese medicine market.
in the overall statin and lipid-lowering proprietary Chinese medicine market.
The Cardiovascular, Renal and Metabolic Division is one of the four major sectors of AstraZeneca China's business structure, and the five major products in the "cardiovascular field" of AstraZeneca China's website, and the Zhikang capsule (0.
3g) ranks among them
.
Dong Zecheng believes that multinational pharmaceutical companies doing research and development of traditional Chinese medicine are certainly not arbitrarily choosing product lines, and will match
resources on their existing product pipelines.
For example, AstraZeneca has a certain research and development and market foundation in the cardiovascular pipeline itself, and when it does Chinese medicine research and development, it is likely to develop in this direction, and form a synergy
between chemical medicine and traditional Chinese medicine in the future.
According to the first half of 2022, AstraZeneca's total revenue was US$22.
2 billion, a year-on-year increase of 48%.
Affected by volume procurement, medical insurance negotiations and the epidemic, China's revenue declined slightly to about US$3.
057 billion
.
2 billion, up 48%
year-on-year.
Affected by volume procurement, medical insurance negotiations and the epidemic, China's revenue declined slightly to about US$3.
057 billion
.
The impact of pharmaceutical policies such as quantitative procurement on the development of pharmaceutical companies is self-evident, which may be one of
the reasons why AstraZeneca chose to deploy traditional Chinese medicine in China.
"The state has been vigorously supporting the development of traditional Chinese medicine, multinational pharmaceutical companies also want to do some development of traditional Chinese medicine, because of its good promotion resources, so multinational pharmaceutical companies to do Chinese medicine research and development innovation has certain advantages
.
" But at the same time, it should be noted that the promotion of Chinese medicine and the logic of chemical medicine are not the same
.
The above-mentioned pharmaceutical company sources further pointed out
.
03 Multinational pharmaceutical companies have entered traditional Chinese medicine
03 Multinational pharmaceutical companies have entered traditional Chinese medicineIn recent years, with the help of many favorable policies of the state, the inheritance and innovation of traditional Chinese medicine has entered a new stage
.
According to the "2021 China Traditional Chinese Medicine Industry Innovation and Development Briefing", in the next five years, the market size of China's traditional Chinese medicine industry will maintain a compound annual growth rate of about 14.
2% and continue to grow rapidly, and by 2025, the market size is expected to reach 5 trillion yuan
.
.
In the context of centralized procurement, the situation of "involution" of chemical drugs is becoming increasingly prominent
.
Based on this, many multinational pharmaceutical companies have chosen to bet their hope of seeking breakthroughs on traditional Chinese medicine
.
In addition to AstraZeneca, multinational pharmaceutical companies such as Sanofi and Boehringer Ingelheim have also laid out the traditional Chinese medicine industry
.
For example, in 2014, Boehringer Ingelheim reached a cooperation with Guangzhou Pharmaceutical Group to promote Pediatric Seven Star Tea Syrup, a subsidiary of Guangzhou Pharmaceutical; In 2015, Boehringer Ingelheim announced the official launch
of its first proprietary Chinese medicine OTC product, Lecoton.
Industry insiders said that multinational pharmaceutical companies' entry into the field of traditional Chinese medicine is divided into three stages, namely the raw material procurement period, the market wait-and-see period and the in-depth cooperation period
.
Judging from the performance of all parties, it has now developed to the third stage
.
.
Judging from the performance of all parties, it has now developed to the third stage
.
In August this year, Jianmin Group, a leading leader in children's proprietary Chinese medicines, announced that its wholly-owned subsidiary, Yekai Thai Pharmaceutical Co.
, Ltd.
, would cooperate with Ping'an Jincun to establish a new proprietary Chinese medicine joint venture "Jincun Jianmin Pharmaceutical"
.
Heian Tsumura is a joint venture between Ping An Life Insurance of China and Tsumura Co.
, Ltd.
, with Tsumura of Japan holding 56% of the shares and absolutely controlling Heian Tsumura
.
After layers of equity calculations, the "Tsumura Kenmin Pharmaceutical" established this time will be actually controlled
by Tsumura of Japan.
Tsumura is a giant of Japanese Kampo medicine, and since its entry into China in 1991, it has gradually improved the industrial chain from the cultivation, processing and production of raw materials for traditional Chinese medicine, and this is its first foray into the field of
proprietary Chinese medicine.
According to public data, Tsumura's revenue exceeded 100 billion yen in 1991, but its revenue has only just risen to 130.
8 billion yen
until 2020.
Given the time span, this growth rate is relatively slow
.
Therefore, some industry insiders said that Tsumura chose to cooperate with Jianmin is likely to be making a layout for opening up the Chinese market to achieve new profit growth
.
.
Large multinational pharmaceutical companies such as AstraZeneca and Tsumura have entered the field of traditional Chinese medicine, which has caused widespread debate
in the industry.
Some supporters believe that the above-mentioned multinational pharmaceutical companies have strong financial resources and strong brand advantages, and the products they produce have high social recognition, which is conducive to hospital sales; Opponents argue that traditional Chinese medicine is a treasure of Chinese civilization, and handing it over to multinational enterprises can easily lead to the outflow
of state-secret formulas.
of state-secret formulas.
Some experts told Cyberblue that from a technical point of view, the advanced experience of multinational pharmaceutical companies in drug research and development can help the Chinese medicine industry solve problems
in quality standards and pharmacodynamic principles.
In addition, the entry of multinational pharmaceutical companies into the field of traditional Chinese medicine can produce a "catfish effect" and force China's pharmaceutical industry to move forward
.
.
However, he said that Chinese have a special affection for Chinese medicine, so try to follow the original style in the packaging of products, so as not to cause patients to have a rebellious psychology and affect drug sales
.
